When combining these two clinical features, patients presenting both mRSS score > 15 and PAH showed the highest prevalence of anti-TRIM21/Ro52 antibodies (100%) (Figure 3c). This evidence concerns the gene TRIM21 and pulmonary arterial hypertension.